WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Rubriques :
Maroc - AFRICANEWSWIRE.ZA.COM - A La Une - 07/Nov 13:25
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences: Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, […]
Articles similaires
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
arabnewsnetwork.ps - 07/Nov 13:25
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global...
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
qatarnewswire.qa - 07/Nov 13:25
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global...
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
menafocus.qa - 07/Nov 13:25
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global...
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
pressarabia.qa - 07/Nov 13:25
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global...
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
varabnewsexpress.ae - 07/Nov 13:25
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global...
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
mideastnews.ae - 07/Nov 13:25
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global...
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
drugs.com - 12/Nov 18:11
CHICAGO and FORT WORTH, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the...
FDA Approves Aucatzyl (obecabtagene autoleucel) for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
drugs.com - 08/Nov 21:11
LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early-commercial stage biopharmaceutical company developing...
Les derniers communiqués
-
Aucun élément